Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Cancer "Quality Of Care" Data Show "A Lot Of Variations," McClellan Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Preliminary data from the oncology demonstration project show variable quality-of-life outcomes, likely because many patients have late-stage cancer, CMS Administrator McClellan says. The program may ultimately help drive improvements in clinical practices, he predicts.

You may also be interested in...

Amgen “Off To Strong Start” Under ASP Reimbursement System

“As each day goes by, we feel better” about ASP-based reimbursement for Medicare Part B drugs, CEO Sharer says. CMS’ “quality of care” demonstration project helps Amgen’s first quarter performance, resulting in increased guidance for 2005. Company execs predict the demo program will continue into 2006 due to “strong lobbying.”

Medicare Cancer Demo May Encourage Use Of EPO, Anti-Emetics

The Medicare program is earmarking $300 mil. for a "quality of care" demonstration project that should help smooth the transition to ASP-based reimbursement in 2005

Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues

“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts